Imaging Biometrics Returns to Profit, but Cash Position Keeps Funding Risk in Focus

Imaging Biometrics Limited returned to profitability during the first half of 2026, helped by tight cost control and a sharper focus on its core medical imaging technologies.

The headline improvement is meaningful. Revenue rose by 6% to £416,270, while administrative expenses fell by 32% to £325,860. That turned an operating loss of £89,652 in the comparable period into an operating profit of £88,678.

However, shareholders should look beyond the income statement. Cash fell to £49,384, the Group had net current liabilities of £226,882, and the accounts state that additional funding will be required through either an equity issue or convertible loan notes.

The full figures and accompanying statements are available in the original company announcement.

Imaging Biometrics' key half-year figures

Metric	H1 2026	H1 2025	Change
Revenue	£416,270	£394,002	Up 6%
Gross profit	£414,536	£389,958	Up 6%
Administrative expenses	£325,860	£479,611	Down 32%
Operating profit or loss	£88,678 profit	£89,652 loss	£178,330 improvement
Profit or loss after tax	£73,852 profit	£89,652 loss	More than £163,000 swing
Earnings per share	0.03p	0.04p loss	Returned to profit
Period-end cash	£49,384	£72,359	Lower

The result shows that Imaging Biometrics can produce an accounting profit at its current revenue level if costs remain controlled. Gross profit was almost equal to revenue because the reported cost of sales was only £1,734.

The improvement was primarily driven by lower expenses rather than rapid sales growth. That distinction matters. Cost reductions can restore profitability, but sustainable progress will eventually depend on converting clinical interest into recurring commercial revenue.

IB Clinic carries the main commercial opportunity

IB Clinic provides automated, quantitative imaging biomarkers for neuro-oncology. In simpler terms, its software extracts objective measurements from brain scans to help clinicians assess tumours and treatment response.

Several institutions moved towards full clinical adoption during the period, with a number expected to complete this process in the third quarter of 2026. The value of these implementations will depend on whether they lead to sustained use and recurring revenue. The company did not disclose expected contract values or revenue per institution.

Clinical evidence also advanced. Results from the EAF151 Phase II study were presented at the American Society of Clinical Oncology Annual Meeting in May 2026.

The prospective study covered 146 patients across 33 sites. It found that fully automated standardised relative cerebral blood volume measurements generated using IB Neuro had the strongest statistically significant association with overall survival, outperforming conventional manual methods.

This does not automatically guarantee commercial adoption, but independent clinical validation can strengthen discussions with neuro-oncology centres, clinical trial sponsors and potential strategic partners.

Imaging Biometrics is also continuing work with GE HealthCare to onboard IB Clinic and QSMetric into GE's global ordering and fulfilment systems. GE is described as actively engaged and committed to completing the integration, although no completion date or financial terms were disclosed.

Partner Prism Clinical Imaging has helped generate interest, including a new platform trial at a major paediatric hospital expected to begin later in 2026. The institution and financial contribution were not disclosed.

IB Nimble moves beyond heavy development

IB Nimble is a secure collaboration platform that allows distributed clinical teams to review images, annotations, quantitative results and patient case information.

Management says the core architecture and major development milestones are complete. Engineering resources can therefore move towards customer support, functionality, performance and user experience rather than the heavy work of constructing the platform.

The company has also adopted artificial intelligence development tools to support coding, reviews, troubleshooting and customer service. The potential benefit is more efficient product development, although the announcement does not quantify any expected savings or revenue contribution.

This shift matters because capitalised intangible asset purchases used £70,905 of cash during the half. Reducing the intensity of development spending could help cash generation, provided commercial adoption follows.

GaM offers optionality, not near-term certainty

The gallium maltolate programme, known as GaM, is aimed at rare paediatric brain cancers. The Board wants to find a partner capable of funding and managing further clinical development and regulatory review.

GaM has received Rare Pediatric Disease Designation for two indications, alongside two Orphan Drug Designations and Fast Track status from the US Food and Drug Administration.

There is theoretical upside from a Rare Pediatric Disease Priority Review Voucher. The company reported that recent third-party voucher transactions had ranged from approximately US$150 million to US$205 million.

That figure needs considerable context. Eligibility would require approval for a qualifying product by 30 September 2029, and the Board says meeting the current deadline is highly unlikely. GaM has not been administered to paediatric patients, the Phase 1 GABRIEL study has not started recruitment, commercial drug supply arrangements have not been secured, and Imaging Biometrics cannot fund a registrational programme itself.

Investors should therefore treat a voucher as possible additional upside rather than a core valuation argument, which is also the Board's stated position.

Kirkstall provides another route to growth

Kirkstall traded profitably during the six months while continuing to invest in market development. It sells Quasi Vivo organ-on-a-chip systems to academic, research and commercial laboratories.

In May, Kirkstall was named as an industry collaborator on a Nottingham Trent University-led programme to develop a glioblastoma tumour-on-a-chip model. The project aims to reproduce the blood-brain barrier and tumour environment within one microfluidic system, potentially improving preclinical drug testing.

Commercial work is continuing through distribution partners in China and the US, alongside direct activity in the American toxicology market. Revenue and profit figures for Kirkstall were not disclosed separately.

Profitability has not removed the balance-sheet risk

The most important negative in these results is liquidity.

Cash declined by £63,226 during the half to £49,384. Although operating activities produced a £9,861 cash inflow, investing activities used £73,087, primarily through purchases of intangible assets.

Trade and other receivables increased to £373,343 from £177,593 at the end of 2025. Meanwhile, trade and other payables stood at £697,594, leaving net current liabilities of £226,882.

Most importantly, the going concern statement says the Group's forecasts show that additional funding will be required, either through an equity issue or convertible loan notes. The chief executive has provided a letter of financial support, and the directors remain reasonably confident that funds will be available when needed.

For existing shareholders, a future equity raise could cause dilution. Convertible loan notes may also ultimately increase the share count. The timing, size and terms of any financing were not disclosed.

What investors should watch next

Imaging Biometrics has delivered a credible turnaround in reported profitability. The combination of 6% revenue growth and a 32% reduction in administrative expenses is a clear operational improvement.

The next test is whether IB Clinic adoption accelerates sufficiently to turn modest growth into sustained recurring revenue. Investors should watch for completed clinical implementations, progress with the GE HealthCare integration, commercial evidence from Prism's activity and further independent validation of the imaging products.

Cash remains the immediate constraint. Until the Group strengthens its liquidity or secures funding on acceptable terms, the improved profit figure should be viewed alongside meaningful financing and dilution risk.

The first half was a positive step, but commercial conversion and balance-sheet resilience will determine whether Imaging Biometrics can make profitability sustainable.